Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$462.13 USD
+5.26 (1.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $461.89 -0.24 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Vertex Pharmaceuticals Incorporated has a market cap of $117.32B, which represents its share price of $456.87 multiplied by its outstanding shares number of 256.80M. As a large-cap company, VRTX's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VRTX 462.13 +5.26(1.15%)
Will VRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRTX
Stay Ahead of the Game With Vertex (VRTX) Q2 Earnings: Wall Street's Insights on Key Metrics
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Vertex Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Other News for VRTX
Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more
KBRA Assigns Preliminary Ratings to VRTX 2025-HQ | VRTX Stock News
Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today
Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200
ClearBridge Growth Portfolios Q2 2025 Commentary